Jae Cheol Park

Jae Cheol Park

Auto-generated profile, based on publicly available information

Jae Cheol Park

Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2020 in Intestinal Research
Verified
Journal Article
Open access
PDF file
SPSang Hyoung Park
Sang Hyoung Park
JPJae Cheol Park
Jae Cheol Park
MLMilan Lukas
Milan Lukas
MKMartin Kolar
Martin Kolar
ELEdward Loftus
Edward Loftus
The inflammatory bowel diseases (IBD), which consist of Crohn's disease and ulcerative colitis, are chronic, incurable immunemediated inflammatory disorders of the intestine. As IBD incidence continues to increase globally and its mortality is low, prevalent cases of IBD are rapidly increasing, thereby leading to a substantial increase in health care costs. Although the introduction of biologic agents for IBD management has revolutionized the armamentarium of IBD therapy, the high cost of this therapy is concerning. With the expirations of patents for existing biologic agents (originals), biosimilars with cheaper costs have been highlighted in the field of IBD. Despite concerns regarding their short- and long-term efficacy, safety, immunogenicity, and interchangeability, increasing evidence via prospective observations and phase III or IV clinical trials, which aim to prove the "biosimilarity" of biosimilars to originals, has partly confirmed their efficacy, safety, and interchangeability. Additionally, although patients and physicians are reluctant to use biosimilars, a positive budget impact has been reported owing to their use in different countries. In the near future, multiple biosimilars with lower costs, and efficacy and safety profile similar to originals, could be used to treat IBD; thus, further consideration and knowledge dissemination are warranted in this new era of biosimilars.

25 May 2022 in Gut and Liver
Verified
Journal Article
Open access
PDF file
HHHee Seung Hong
Hee Seung Hong
JBJiwon Baek
Jiwon Baek
JPJae Chul Park
Jae Chul Park
HLHo-Su LEE
Ho-Su LEE
DPDohoon Park
Dohoon Park
ODon behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Hee Seung Hong, Jiwon Baek, Jae Chul Park, Ho-Su Lee, Dohoon Park, A-Ran Yoon, Soo Jung Park, Sung Noh Hong, Seong-Joon Koh, Chang Kyun Lee, Bo-In Lee, Sung Wook Hwang, Sang Hyoung Park, Seung-Jae Myung, Suk-Kyun Yang, Kyuyoung Song, and Byong Duk Ye, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Gut and Liver 2022;16:942-51. https://doi.org/10.5009/gnl210415

30 September 2023 in The Journal of Korean Academy of Physical Therapy Science
Verified
Journal Article
Closed access
JPJae Cheol Park
Jae Cheol Park
JJJin Gyu Jeong
Jin Gyu Jeong